Akamprosat

Akamprosat
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	20 - 33 h
Izlučivanje	Renalno
Identifikatori
CAS broj	77337-76-9
ATC kod	N07BB03 (WHO)
PubChem	CID 71158
DrugBank	DB00659
ChemSpider	64300
ChEBI	CHEBI:51041
ChEMBL	CHEMBL1201293
Hemijski podaci
Formula	C5H11NO4S
Molarna masa	181,210
	SMILES CC(=O)NCCCS(O)(=O)=O; ;
	InChI InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10) ; Key:AFCGFAGUEYAMAO-UHFFFAOYSA-N ;

Akamprosat je organsko jedinjenje, koje sadrži 5 atoma ugljenika i ima molekulsku masu od 181,210 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	4
Broj donora vodonika	2
Broj rotacionih veza	4
Particioni koeficijent^[8] (ALogP)	-1,2
Rastvorljivost^[9] (logS, log(mol/L))	-0,6
Polarna površina^[10] (PSA, Å²)	91,8

Reference

^ Williams SH: Medications for treating alcohol dependence. Am Fam Physician. 2005 Nov 1;72(9):1775-80. PMID Williams, Steven H. (новембар 2005). „Medications for treating alcohol dependence”. American Family Physician. 72 (9): 1775—1780. PMID 16300039.
^ Mason BJ: Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. Mason, B. J. (2001). „Treatment of alcohol-dependent outpatients with acamprosate: A clinical review”. J Clin Psychiatry. 62 Suppl 20: 42—48. PMID 11584875. ;62 Suppl 20:42-8.
^ Mason BJ, Goodman AM, Chabac S, Lehert P: Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. Mason, B.; Goodman, A.; Chabac, S.; Lehert, P. (2006). „Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation”. J Psychiatr Res. 40 (5): 383—393. PMID 16546214. doi:10.1016/j.jpsychires.2006.02.002. Aug;40(5):383-93. Epub 2006 Mar 20.
^ Feeney GF, Connor JP, Young RM, Tucker J, McPherson A: Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006 May-Jun;41(3):321-7. Epub 2006 Feb 8. PMID Feeney, Gerald F. X.; Connor, Jason P.; Young, Ross McD.; Tucker, Jane; McPherson, Annie (2006). „Combined Acamprosate and Naltrexone, with Cognitive Behavioural Therapy is Superior to Either Medication Alone for Alcohol Abstinence: A Single Centres' Experience with Pharmacotherapy”. Alcohol and Alcoholism. 41 (3): 321—327. PMID 16467406. doi:10.1093/alcalc/agl007.
^ Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998;49:173-84. PMID Tsai, G.; Coyle, J. T. (1998). „See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. Pubmed:http://www.ncbi.nlm.nih.gov/pubmed/18711953 9509257 See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. Pubmed:http://www.ncbi.nlm.nih.gov/pubmed/18711953”. Annual Review of Medicine. 49: 173—184. PMID 9509257. doi:10.1146/annurev.med.49.1.173. Спољашња веза у |title= (помоћ)
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. Текст „noedit” игнорисан (помоћ)
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. Текст „noedit” игнорисан (помоћ)
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. Текст „noedit” игнорисан (помоћ)

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Acamprosate

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Williams SH: Medications for treating alcohol dependence. Am Fam Physician. 2005 Nov 1;72(9):1775-80. PMID Williams, Steven H. (новембар 2005). „Medications for treating alcohol dependence”. American Family Physician. 72 (9): 1775—1780. PMID 16300039.

[2] Mason BJ: Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. Mason, B. J. (2001). „Treatment of alcohol-dependent outpatients with acamprosate: A clinical review”. J Clin Psychiatry. 62 Suppl 20: 42—48. PMID 11584875. ;62 Suppl 20:42-8.

[3] Mason BJ, Goodman AM, Chabac S, Lehert P: Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. Mason, B.; Goodman, A.; Chabac, S.; Lehert, P. (2006). „Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation”. J Psychiatr Res. 40 (5): 383—393. PMID 16546214. doi:10.1016/j.jpsychires.2006.02.002. Aug;40(5):383-93. Epub 2006 Mar 20.

[4] Feeney GF, Connor JP, Young RM, Tucker J, McPherson A: Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006 May-Jun;41(3):321-7. Epub 2006 Feb 8. PMID Feeney, Gerald F. X.; Connor, Jason P.; Young, Ross McD.; Tucker, Jane; McPherson, Annie (2006). „Combined Acamprosate and Naltrexone, with Cognitive Behavioural Therapy is Superior to Either Medication Alone for Alcohol Abstinence: A Single Centres' Experience with Pharmacotherapy”. Alcohol and Alcoholism. 41 (3): 321—327. PMID 16467406. doi:10.1093/alcalc/agl007.

[5] Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998;49:173-84. PMID Tsai, G.; Coyle, J. T. (1998). „See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. Pubmed:http://www.ncbi.nlm.nih.gov/pubmed/18711953 9509257 See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. Pubmed:http://www.ncbi.nlm.nih.gov/pubmed/18711953”. Annual Review of Medicine. 49: 173—184. PMID 9509257. doi:10.1146/annurev.med.49.1.173. Спољашња веза у |title= (помоћ)

[6] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[7] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. Текст „noedit” игнорисан (помоћ)

[8] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.

[9] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. Текст „noedit” игнорисан (помоћ)

[10] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. Текст „noedit” игнорисан (помоћ)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]